Literature DB >> 9665191

Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity. The Pediatric Hematology Working Group in the Czech Republic.

O Hrusák1, J Trka, J Zuna, J Housková, J Bartůnková, J Starý.   

Abstract

The antigen KOR-SA3544 is physiologically expressed exclusively on granulocytes. Aberrant expression of KOR-SA3544 has been invariably found in BCR/ABL-positive acute lymphoblastic leukemia (ALL) and in some BCR/ABL-negative ALL. In an interim analysis of a prospective clinical and cytometric study data of 73 children with newly diagnosed or relapsed ALL with and without TEL/AML1 fusion are presented. KOR-SA3544 expression over 3% was detected in the majority of TEL/AML1-negative patients with newly diagnosed common or preB ALL (19 of 31) and not in TEL/AML1-positive patients (0 of 18, P < 0.0001). The level of expression of KOR-SA3544 was 0.02-90% (median 6.0%) and 0.03-2.4% (median 0.23%) in TEL/AML1-negative and TEL/AML1-positive patients, respectively. All five newly diagnosed patients with DNA index > or =1.16 and <1.6 exhibited high levels of KOR-SA3544 expression. Membrane expression of CD79a was found to correlate with TEL/AML1 negativity, although less significantly than KOR-SA3544 (P = 0.03). Furthermore, our data confirm that TEL/AML1 positivity correlates with non-hyperdiploidy and low presenting age. In conclusion, KOR-SA3544 correlated strongly with TEL/AML1 negativity, it was a better predictor of TEL/AML1 status than other factors tested and was found at high levels in hyperdiploidy. In combination with age, KOR-SA3544 predicted TEL/AML1 status in 86% newly diagnosed preB/cALL patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665191     DOI: 10.1038/sj.leu.2401072

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.

Authors:  Jana Volejnikova; Ester Mejstrikova; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimir Mihal; Jaroslav Sterba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Zdenka Cerna; Ondrej Hrusak; Jan Stary; Jan Trka; Eva Fronkova
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

2.  Machine Learning Based Analysis of Relations between Antigen Expression and Genetic Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia.

Authors:  Jan Kulis; Łukasz Wawrowski; Łukasz Sędek; Łukasz Wróbel; Łukasz Słota; Vincent H J van der Velden; Tomasz Szczepański; Marek Sikora
Journal:  J Clin Med       Date:  2022-04-19       Impact factor: 4.964

3.  Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemias.

Authors:  Richard Ratei; Leonid Karawajew; Richard Schabath; Angelika Ehrfeldt; Fritz Grunert; Wolf-Dieter Ludwig
Journal:  Int J Hematol       Date:  2008-02-27       Impact factor: 2.490

4.  Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.

Authors:  Tomas Kalina; Martina Vaskova; Ester Mejstrikova; Jozef Madzo; Jan Trka; Jan Stary; Ondrej Hrusak
Journal:  BMC Cancer       Date:  2005-04-12       Impact factor: 4.430

Review 5.  Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction.

Authors:  Jan Kulis; Łukasz Sędek; Łukasz Słota; Bartosz Perkowski; Tomasz Szczepański
Journal:  Genes (Basel)       Date:  2022-07-31       Impact factor: 4.141

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.